ArticleBreathe (Sheffield, England)2023
Treatment-shortening regimens for tuberculosis: updates and future priorities.
Article in Breathe (Sheffield, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between HIV and acquisition of rifamycin resistance with first-line TB treatment: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- The role of the UNITE4TB Young Investigators Group in empowering early career researchers through mentorship, capacity building, and innovation.IJTLD open · 2026Article
- Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocol.BMJ open respiratory research · 2025Article
- Impact of HIV and hospitalization on the incidence of subsequent rifampicin-resistant tuberculosis after initiation of first-line tuberculosis treatment: a retrospective cohort study in South Africa.EClinicalMedicine · 2025Article
- Time to sputum culture conversion and associated factors in multidrug-resistant tuberculosis patients in Southwestern Oromia, Ethiopia: a ten-year retrospective follow-up study.BMC pulmonary medicine · 2025Article
- A New Era in Tuberculosis Prevention and Treatment: Breakthroughs in Drug Development and Future Prospects.Infectious diseases and therapy · 2025Review
- Comparing cost-effectiveness of short-course regimens for drug-resistant tuberculosis treatment in India.International journal of technology assessment in health care · 2025Article
- Bridging science and policy in tuberculosis treatment through innovations in precision medicine, drug development, and cohort research: a narrative review.Ewha medical journal · 2025Review
- Structural and mechanistic study of a novel inhibitor analogue ofnpj drug discovery · 2025Article
- Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital.Antibiotics (Basel, Switzerland) · 2024Article
- Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.The Lancet. Infectious diseases · 2024Observational
- Article
- People first: a participatory community approach on patient-reported outcomes in tuberculosis.Breathe (Sheffield, England) · 2024Article
- Review
- The changing face of the modern respiratory clinician.Breathe (Sheffield, England) · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past 2 years, remarkable advances have been made in shortening tuberculosis (TB) treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB-PRACTECAL) have provided evidence of the efficacy of regimens based on new and repurposed drugs: the 4-month regimen for drug-susceptible TB, and the 6-month bedaquiline-pretomanid-linezolid regimen with or without moxifloxacin for multidrug-resistant/rifampicin-resistant TB. Even if the evidence at the basis of these new regimens is compelling, several questions remain open, particularly concerning linezolid dose finding, the upsurging threat of bedaquiline-resistant
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.